article thumbnail

Preventative approach could reduce immunotherapy side effects

European Pharmaceutical Review

Immunotherapy drugs like teclistamab can result in potentially fatal side effects, including CRS and immune cell-associated neurotoxicity syndrome (ICANS). In 2022, the drug was approved by the US Food and Drug Administration (FDA) for these patients. We are going with full steam into an era of immunotherapy.”

article thumbnail

Lilly has a new blockbuster

World of DTC Marketing

Food and Drug Administration approved Eli Lilly’s novel treatment for diabetes. Mounjaro, Lilly’s new diabetes drug, is sure to be in high demand initially after launch, but patients should be aware of its side effects. Will patients look past those side effects to lose weight? A matter of trust?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Are new weight loss drugs an answer or problem?

World of DTC Marketing

Unpaid celebrity endorsements include venture capitalist Marc Andreessen, who says the drug completely changed his relationship with food, and Elon Musk, who has cited it on Twitter. It has to persuade patients to sign up for some heinous side effects. So far, the data for Wegovy looks excellent.

article thumbnail

A scientific approach to irrational consumer choices

World of DTC Marketing

A review, authored by researchers at RTI International and the US Food and Drug Administration (FDA), looked at 38 studies published between 1982 and 2017 that examined outcomes reported by patients, prescribers, or both regarding their experience with DTC advertising in the US and New Zealand.

article thumbnail

Is it too late for Biogen?

World of DTC Marketing

The critics have also expressed concerns about whether the drug’s benefits, which appeared to be modest in studies, are worth the risks of side effects such as brain bleeding that require regular physician monitoring. Food and Drug Administration on Biogen Inc.’s Top researchers who advised the U.S.

article thumbnail

FDA approves first drug to delay type 1 diabetes

European Pharmaceutical Review

Tzield (teplizumab-mzwv), the first drug to help prolong the onset of stage 3 type 1 diabetes in adults and children over eight years old with stage 2 type 1 diabetes, has been approved by the US Food and Drug Administration (FDA). Tzield clinical trials that supported the US Food and Drug Administration approval.

article thumbnail

MHRA warns of serious eye-related adverse events after Dupixent use

Pharmaceutical Technology

On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.